We give you access to a high-quality pipeline of pharma-relevant healthtech startups. You co-select ventures, invest directly, and help shape their development — with no carry, no pooling, and no equity or fees to DayOne.

We ask for a soft commitment of CHF 250,000 per year. It’s non-binding and flexible:

• If unused, it rolls over to the next cohort
• After two cohorts without investment, we review the partnership

No. You invest only in the startups you choose. Your soft commitment ensures we can give startups confidence that funding is likely — but the decision is always yours.

Yes. CHF 250K is a baseline. You’re welcome to invest more in one or multiple startups depending on your interest and conviction.

1. You sign a partner agreement 
2. You join the selection committee (with pharma experts) 
3. You help select the top 15 startups for the accelerator 
4. After 4 months, 3 startups enter the post-accelerator 
5. You invest directly using our legal templates (or your own, with limited support) 

We offer Swiss-compliant convertible loan and equity term sheet templates. These are founder-friendly but investor-aligned.
If you want to lead a deal on your own terms, you are free to do so — we just may not coordinate the legal process if it differs from our structure.

No. DayOne is a non-profit and takes no equity, no fees, and no carry. We provide infrastructure, support, and coordination — but all investment goes directly between you and the startup.

Pharma experts sit on the selection committee and support the ventures throughout. Their involvement ensures startups address real industry problems and gain strategic visibility.

Startups selected for the post-accelerator and receiving your investment get a CHF 50K non-dilutive grant, if they also establish a presence in the Basel Area. This boosts runway and de-risks your investment.

Startups that enable or accelerate pharmaceutical R&D:

• Digital health, techbio, AI/ML for drug discovery or trials
• Diagnostics, decision-support tools, data platforms
• IP-protected or early-traction companies
  All are selected from a global funnel and vetted by both investors and pharma.